tacalyx
Tacalyx is a biotech company that develops novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs). The company utilizes a discovery platform to create antibody-based immunotherapeutics, including Antibody-Drug Conjugates (ADCs), for the treatment of various human cancers. It operates as a spin-out from the Max-Planck-Institute of Colloids and Interfaces.
Visit websiteBerlin, Germany
Biotechnology
Oncology
Pharmaceuticals
Healthtech
Funding summary
- Total raised
- €18.0M
- Funding rounds
- 2
Investors in tacalyx
Investors on record for tacalyx. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like tacalyx?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors